Get the Stockscreener App
89.75
7.06%
-6.82
After Hours:
89.75
Blueprint Medicines Corp Stock (BPMC) Latest News
Blueprint Medicines stock target holds at $125 by Citizens JMP - Investing.com
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress - PR Newswire
Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire
Blueprint Medicines’ SWOT analysis: stock outlook amid Ayvakit’s growth - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Reduced by Rhumbline Advisers - Defense World
Blueprint Medicines COO Christina Rossi sells shares for $216,348 By Investing.com - Investing.com South Africa
Blueprint Medicines COO Christina Rossi sells shares for $216,348 - Investing.com
Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
Blueprint Medicines Co. (NASDAQ:BPMC) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Van ECK Associates Corp - Defense World
Blueprint Medicines (NASDAQ:BPMC) Releases Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
989 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Asset Management One Co. Ltd. - Defense World
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - Defense World
Stifel maintains Blueprint Medicines stock Buy rating, $155 target By Investing.com - Investing.com South Africa
Stifel maintains Blueprint Medicines stock Buy rating, $155 target - Investing.com
Blueprint Medicines' SWOT analysis: strong ayvakit sales fuel growth as stock eyes $140 - Investing.com
What is Leerink Partnrs’ Forecast for BPMC Q1 Earnings? - Defense World
Blueprint Medicines (NASDAQ:BPMC) Lowered to Sell Rating by StockNews.com - Armenian Reporter
Stephens Inc. AR Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at Needham & Company LLC - Defense World
HC Wainwright Reaffirms “Buy” Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Blueprint Medicines (NASDAQ:BPMC) Rating Lowered to “Sell” at StockNews.com - Defense World
Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Wedbush Reiterates Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline - Nasdaq
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines price target raised to $135 from $127 at Baird - TipRanks
Blueprint Medicines Corporation (NASDAQ:BPMC) Is Expected To Breakeven In The Near Future - Simply Wall St
Strong Buy Rating for Blueprint Medicines: Ayvakit’s Growth Potential and Market Opportunities - TipRanks
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ... - Yahoo Finance
Blueprint Medicines Reports Strong Growth and Promising Outlook - TipRanks
Blueprint Medicines: Positive Earnings Call Highlights Growth - TipRanks
Blueprint Medicines Corp SEC 10-K Report - TradingView
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views - Benzinga
Blueprint Medicines: Q4 Earnings Snapshot - The Washington Post
Blueprint Medicines should be bought on any weakness, says Stifel - TipRanks
Earnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimates - MSN
Blueprint Medicines Corp earnings missed by $0.09, revenue fell short of estimates - Investing.com
Values First Advisors Inc. Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines selloff to be short-lived, says Oppenheimer - TipRanks
Earnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimates By Investing.com - Investing.com UK
Blueprint Medicines Corp Reports Q4 Revenue of $144.1 Million, M - GuruFocus.com
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (BPMC) Blueprint Medicines Posts Q4 Net Loss $-0.79 a Share, vs. FactSet Est of $-0.67 Loss - Marketscreener.com
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - TradingView
BLUEPRINT MEDICINES Earnings Results: $BPMC Reports Quarterly Earnings - Nasdaq
Blueprint Medicines reports Q4 EPS (79c), consensus (71c) - TipRanks
Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday - Defense World
Research Analysts Offer Predictions for BPMC FY2025 Earnings - MarketBeat
Get in on Blueprint Medicines Corp’s (BPMC) buy-in window today! - SETE News
Leerink Partnrs Issues Pessimistic Outlook for BPMC Earnings - Defense World
Jennison Associates LLC Invests $31.42 Million in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Balance Sheet Dive: Blueprint Medicines Corp (BPMC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Should You Buy Blueprint Medicines (BPMC) After Golden Cross? - Nasdaq
How to interpret Blueprint Medicines Corp (BPMC)’s stock chart patterns - US Post News
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 - Financial Times
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by KBC Group NV - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Significant Increase in Short Interest - MarketBeat
Taking on analysts’ expectations and winning: Blueprint Medicines Corp (BPMC) - SETE News
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by SG Americas Securities LLC - Defense World
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):